LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Other Events
The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.1.
Additionally, the Company will be meeting with investors and presenting materials regarding the Company at the H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. The Company’s materials to be used in the presentations are filed hereto as Exhibit 99.2.
|99.2||H.C. Wainwright BioConnect 2021 Presentation|
Lipocine Inc. Exhibit
EX-99.1 2 tm2039447d2_ex99-1.htm EXHIBIT 99.1 Enabling Oral Drug Delivery to Improve Patient Compliance January 2021 Corporate Presentation Exhibit 99.1 Forward – Looking Statements This presentation contains forward – looking statements about Lipocine Inc . (the “Company”) . These forward – looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . These forward – looking statements relate to the Company’s products and product candidates,…
To view the full exhibit click
About LIPOCINE INC. (NASDAQ:LPCN)
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.